Nonalcoholic Fatty Liver Disease (NAFLD)

by

Tatjana Ábel, Gabriella Lengyel

DOI: 10.2174/97816810846571170101
eISBN: 978-1-68108-465-7, 2017
ISBN: 978-1-68108-466-4



Indexed in: EBSCO.

Non-alcoholic fatty liver disease (NAFLD) is a common cause of elevated liver enzymes and chronic liver disease in Western countries. ...[view complete introduction]
US $
Buy Personal eBook
69
Order Library eBook
276
Order Printed Copy
*83
Order PDF + Printed Copy (Special Offer)
*117

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Management of NAFLD

- Pp. 119-136 (18)

Krisztina Hagymási and Gabriella Lengyel

Abstract

Nonalcoholic fatty liver disease and steatohepatitis are the most common chronic diseases of the liver. The process of their development has not yet been fully elucidated. It is characterized by insulin resistance, hepatic lipid accumulation with a secondary pathologic production of free radicals that induce inflammatory processes and fibrosis. There is no evidence-based therapy. It is important to eliminate the pathogenic factors (excess body weight, disordered carbohydrate metabolism, and hyperlipidemia). Potential modalities of a causal therapy include cannabinoid receptor 1 antagonists which do not cross the blood-brain barrier, cannabinoid receptor 2 agonists; selective serotonin 2C receptor agonist, thiazolidinediones, incretins, and dipeptidyl peptidase inhibitors. Additional therapeutic possibilities of the future may target antioxidant defense, immune-mediated mechanisms, apoptosis, and lipogenesis.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science